Efficacy and Safety of Hypofractionated Radiotherapy With a Simultaneous Integrated Boost and With a Sequential Boost After Breast‐Conserving Surgery
Cancer Medicine · 2025
DOI: 10.1002/cam4.70630 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Na Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Tangshan People's Hospital, Tangshan, Hebei, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Mastectomy, Segmental, Radiation Dose Hypofractionation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Scientific Research Fund Progarm of Hebei Provincial Health Commission, Science and Technology Planning Project of Tangshan.
Abstract (Originalsprache)
Purpose
The objective of this study was retrospectively to compare the efficacy and safety of hypofractionated radiotherapy (HFRT) with a simultaneous integrated boost (SIB) or with a sequential boost (SB) after breast‐conserving surgery in patients diagnosed with early breast cancer.
Methods
This study enrolled a total of 343 patients diagnosed with T1‐2N0‐1 breast cancer who had undergone breast‐conserving surgery followed by whole‐breast irradiation (WBI) without nodal irradiation, between March 2018 and April 2021. Out of 343 patients, 176 (51.3%) received HFRT‐SIB treatment, totaling 15 sessions, while the remaining 167 (48.7%) received HFRT‐SB treatment, totaling 18 sessions. Demographic characteristics, skin toxicity, radiation pneumonia, and myelosuppression, were compared in the two groups. Three‐year local progression free survival (LPFS) rates were determined using the Kaplan–Meier method and compared using the log‐rank test.
Results
The median follow‐up time was 39.7 months (range 24.3–61.3 months). Toxicities rates did not differ significantly in the HFRT‐SIB and HFRT‐SB groups, including rates of grade 2 skin toxicity (14.8% vs. 13.8%, p = 0.721), Grade 2 radiation pneumonia (2.8% vs. 3.6%, p = 0.355), grades 1, 2 and 3 myelosuppression (12.5%, 5.7% and 1.1%, respectively, vs. 9.6%, 7.8%, and 1.2%, respectively; p = 0.744). Three‐year cumulative LPFS rates were similar in the HFRT‐SIB and HFRT‐SB groups (99.3% vs. 98.6%, p = 0.52). Regional nodal recurrences were observed in one patient in the HFRT‐SIB group (after 27.4 months) and in two patients in the HFRT‐SB group (after 29.4 and 56.4 months), and a local recurrence was observed in one patient in the latter group after 36.0 months. One patient in the HFRT‐SIB group was diagnosed with distant metastases to bone, and one patient in the HFRT‐SB group was diagnosed with distant metastases to the liver.
Conclusion
Similar efficacy and safety of HFRT‐SIB and HFRT‐SB after breast‐conserving surgery in patients with early‐stage (T1‐2N0‐1) breast cancer. Longer‐term follow‐up is required to further compare their efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Tangshan People's Hospital, Tangshan, Hebei, China.
- Department of Radiochemotherapy, Tangshan People's Hospital, Tangshan, Hebei, China.
Förderung
- The Scientific Research Fund Progarm of Hebei Provincial Health Commission
- Science and Technology Planning Project of Tangshan
Zitieren
APA
Li, N., Zhou, Y., Wang, J., Wang, Y., Shao, R., Yang, H., Xiong, W., Zheng, X., & Wang, X. (2025). Efficacy and Safety of Hypofractionated Radiotherapy With a Simultaneous Integrated Boost and With a Sequential Boost After Breast‐Conserving Surgery. Cancer Medicine. https://doi.org/10.1002/cam4.70630
Vancouver
Li N, Zhou Y, Wang J, Wang Y, Shao R, Yang H, et al. Efficacy and Safety of Hypofractionated Radiotherapy With a Simultaneous Integrated Boost and With a Sequential Boost After Breast‐Conserving Surgery. Cancer Medicine. 2025. doi:10.1002/cam4.70630
BibTeX
@article{Li2025,
author = {Li, Na and Zhou, Yang and Wang, Jianting and Wang, Yuwei and Shao, Ruiyu and Yang, Haifang and Xiong, Wei and Zheng, Xuan and Wang, Xiaohong},
title = {Efficacy and Safety of Hypofractionated Radiotherapy With a Simultaneous Integrated Boost and With a Sequential Boost After Breast‐Conserving Surgery},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.70630}
}
EUVIMED